"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

E. Engelsman, J. C M Klijn, R. D. Rubens, J. Wildiers, L. V A M Beex, M. A. Nooij, N. Rotmensz, R. Sylvester

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of '"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)'. Together they form a unique fingerprint.

Medicine & Life Sciences